Epilepsy in the Elderly
Epilepsy in adults aged ≥65 years represents a growing clinical challenge with unique diagnostic and therapeutic considerations. The elderly population has the highest incidence of new-onset epilepsy of any age group, yet seizures in this population are frequently underrecognized, misdiagnosed, or attributed to other conditions such as delirium, transient ischemic attacks, or cognitive decline. Etiologies differ markedly from younger adults, with cerebrovascular disease accounting for the largest share of identifiable causes. ASM selection in the elderly must account for altered pharmacokinetics, polypharmacy, cognitive vulnerability, falls risk, and bone health. A "start low, go slow" approach guides therapy, with lamotrigine, levetiracetam, and lacosamide emerging as preferred agents in this population.
Bottom Line
- Highest incidence age group: Epilepsy incidence in adults ≥65 exceeds 130–140 per 100,000/year — more than double the rate in younger adults and higher than childhood
- Stroke is the most common identifiable etiology (~30–50% of new-onset epilepsy in elderly), followed by neurodegenerative disease, tumors, and metabolic derangements
- Up to 50% of new-onset epilepsy in the elderly has no identifiable cause and may represent the earliest manifestation of occult cerebrovascular disease or neurodegenerative pathology
- Diagnostic challenge: Nonconvulsive status epilepticus (NCSE) is found in up to 28% of elderly patients with unexplained delirium when continuous EEG is performed
- Preferred ASMs: Lamotrigine (best tolerability evidence), levetiracetam (ease of use, no interactions), and lacosamide (minimal cognitive effects, renal clearance)
- Avoid phenytoin (narrow therapeutic index, drug interactions, osteoporosis, cognitive impairment, gingival hyperplasia) and carbamazepine (hyponatremia, drug interactions, cardiac conduction effects)
- Seizure freedom is achievable in 60–70% of elderly patients with monotherapy at low to moderate doses
Epidemiology
The incidence of epilepsy follows a bimodal distribution, peaking in infancy/early childhood and again after age 60, with the elderly peak now exceeding the childhood peak in developed countries. Population-based studies report an incidence of 130–140 per 100,000/year in those over 65, rising to over 160 per 100,000/year after age 80. The prevalence of active epilepsy in the elderly is estimated at 1–1.5%. As the global population ages, the absolute number of elderly people with epilepsy is increasing rapidly. By 2030, it is projected that the majority of people with newly diagnosed epilepsy will be over 60 years of age in many high-income countries.
Despite this high incidence, epilepsy in the elderly is underdiagnosed. Seizures may present with subtle or atypical features, patients may not recall events (particularly if they live alone), and symptoms are frequently attributed to other common geriatric conditions. Studies suggest that the true incidence may be 2–3 times higher than reported figures.
Etiologies
| Etiology | Proportion | Clinical Features | Key Considerations |
|---|---|---|---|
| Cerebrovascular disease | 30–50% | Post-stroke seizures (acute symptomatic within 7 days; late/unprovoked after 7 days); small vessel disease; hemorrhagic stroke higher risk than ischemic | Late post-stroke seizures (>7 days) constitute epilepsy by definition; cortical involvement increases risk; anticoagulation interactions |
| Neurodegenerative disease | 10–20% | Alzheimer disease (6–10× increased seizure risk), Lewy body dementia, frontotemporal dementia | Seizures may precede clinical dementia by years; "transient epileptic amnesia" as early presentation; subclinical seizures on EEG |
| Brain tumors | 5–10% | Meningiomas, gliomas, metastases; seizures may be presenting symptom | MRI essential in all new-onset elderly epilepsy; enzyme-inducing ASMs interact with chemotherapy |
| Traumatic brain injury | 5–10% | Falls with subdural hematoma; remote TBI from decades earlier | Chronic subdural hematoma often underrecognized; anticoagulation increases bleeding risk |
| Metabolic/toxic | 5–10% | Hyponatremia, uremia, hepatic encephalopathy, hyperglycemia, drug toxicity | Acute symptomatic seizures; treat underlying cause; ASM may not be needed long-term |
| Unknown (cryptogenic) | ~50% | No identifiable etiology on initial workup; may represent occult cerebrovascular disease or early neurodegeneration | "Vascular precursor epilepsy" — new-onset epilepsy in elderly may predict future cerebrovascular events; monitor vascular risk factors |
Clinical Presentation & Diagnostic Challenges
Seizure Semiology in the Elderly
Seizures in the elderly differ from those in younger adults in several important ways. Focal onset seizures predominate (>70%), often arising from temporal or frontal regions. Auras may be absent or unrecognized. The motor component is frequently subtle — brief staring, confusion, or behavioral arrest rather than dramatic tonic-clonic activity. Postictal confusion tends to be prolonged (hours to days vs. minutes in younger patients), and Todd paralysis may be more common. Bilateral tonic-clonic seizures as an initial presentation are less common than in younger adults. Transient epileptic amnesia — recurrent, brief episodes of isolated amnesia — is a distinctive presentation in the elderly that may be the earliest manifestation of Alzheimer disease.
When to Suspect Seizures in the Elderly
- Recurrent episodes of transient confusion or "spells" without a clear medical explanation
- Episodic memory gaps or "lost time" (transient epileptic amnesia)
- Unexplained falls, particularly with tongue biting or urinary incontinence
- Fluctuating consciousness or "delirium" unresponsive to standard treatment
- New-onset repetitive movements (automatisms) in the setting of altered awareness
- Post-stroke confusion that is disproportionate to the lesion size
- Abrupt worsening of cognitive function in a patient with known dementia
Nonconvulsive Status Epilepticus (NCSE) and Delirium
NCSE is a critical diagnostic consideration in elderly patients with unexplained confusion or delirium. A landmark prospective study using continuous EEG monitoring found that 28% of elderly patients with delirium had EEG patterns compatible with NCSE. In over 80% of those cases, the NCSE was initially attributed to another cause (metabolic encephalopathy, medication effect, or dementia). This underscores the importance of maintaining a low threshold for EEG monitoring in elderly patients with unexplained encephalopathy, particularly when confusion is disproportionate to identified medical causes, fluctuates significantly, or fails to improve with treatment of the presumed etiology.
EEG Interpretation in the Elderly
EEG findings in the elderly require careful interpretation due to age-related changes that can mimic pathology and pathologic patterns that may be underrecognized.
| EEG Finding | Significance | Clinical Correlation |
|---|---|---|
| Slowing of posterior dominant rhythm (7–8 Hz) | Normal aging variant; may be confused with mild encephalopathy | Compare with clinical presentation; consistent 8+ Hz PDR suggests normal function |
| Temporal intermittent rhythmic delta activity (TIRDA) | More common in elderly; associated with temporal lobe epilepsy but also occurs in neurodegenerative disease | Supports epilepsy diagnosis when correlated with clinical seizures; alone is not diagnostic |
| Periodic lateralized epileptiform discharges (PLEDs/LPDs) | Common post-stroke; on the ictal-interictal continuum; may represent ongoing subclinical seizure activity | Consider cEEG monitoring; treatment threshold controversial — treat if clinical correlate present |
| Generalized periodic discharges (GPDs) | Often associated with metabolic encephalopathy, CJD, or medication effect in elderly | Work up underlying cause; distinguish from epileptiform activity; triphasic morphology suggests metabolic etiology |
| Temporal sharp waves | Epileptiform; supports epilepsy diagnosis | Sensitivity of single routine EEG only 25–30%; serial or prolonged recordings increase yield to 50–70% |
| Wicket spikes | Normal variant (benign); over-interpreted as epileptiform in 10–15% of cases | Arciform, 6–11 Hz, temporal regions; do not prescribe ASMs based on wicket spikes alone |
| Small sharp spikes (BETS) | Benign epileptiform transients of sleep; normal variant | Common in elderly; bilateral, low-amplitude, brief; do not indicate epilepsy |
The sensitivity of a single routine 20-minute EEG for detecting epileptiform activity in the elderly is only 25–30%. Serial EEGs (3 recordings) increase sensitivity to approximately 50%, and prolonged ambulatory or inpatient video-EEG monitoring can achieve yields of 50–70%. Given the high rate of NCSE in elderly patients with unexplained delirium, continuous EEG monitoring should be considered in any elderly patient with altered mental status disproportionate to identified medical causes.
ASM Selection in the Elderly
The principle of "start low, go slow" is paramount in elderly patients. Pharmacokinetic changes of aging include decreased hepatic metabolism (reduced CYP450 activity), reduced renal clearance (GFR declines ~1 mL/min/year after age 40), decreased protein binding (lower albumin), increased body fat (increased volume of distribution for lipophilic drugs), and altered drug absorption. These changes result in higher free drug levels, prolonged half-lives, and increased susceptibility to adverse effects at standard adult doses. Elderly patients also have increased blood-brain barrier permeability, making them more sensitive to CNS effects.
| ASM | Starting Dose (Elderly) | Typical Target Dose | Advantages | Key Concerns |
|---|---|---|---|---|
| Lamotrigine | 25 mg/day | 100–200 mg/day | Best tolerability data (SANAD-II); minimal cognitive effects; mood stabilizing; no drug interactions (non-enzyme-inducing) | Slow titration (8–12 weeks to target); rash risk; possible cardiac conduction effects (ECG at baseline); limited IV formulation |
| Levetiracetam | 250 mg BID | 500–1000 mg BID | No hepatic metabolism; no drug interactions; rapid titration; IV formulation available; broad spectrum | Behavioral side effects (irritability, agitation, depression) — particularly problematic in patients with preexisting psychiatric comorbidity or dementia; renal dosing needed |
| Lacosamide | 50 mg BID | 100–200 mg BID | Minimal cognitive effects; IV formulation; limited drug interactions; well tolerated | PR interval prolongation (ECG before and after titration); avoid with 2nd/3rd degree AV block; renal dosing above CrCl ≤30 |
| Oxcarbazepine | 150 mg BID | 300–600 mg BID | Fewer drug interactions than carbamazepine; effective for focal seizures | Hyponatremia (up to 25–30% of elderly); sodium levels must be monitored; some enzyme induction at high doses |
| Zonisamide | 25–50 mg/day | 100–200 mg/day | Once-daily dosing; weight loss; long half-life | Cognitive slowing; kidney stones; hypohidrosis; slow titration |
| Gabapentin | 100–300 mg/day | 300–600 mg TID | No drug interactions; anxiolytic; neuropathic pain benefit | Sedation; dizziness; falls risk; renal dosing; requires TID dosing; limited efficacy in some epilepsy types |
ASMs to Avoid in the Elderly
- Phenytoin: Narrow therapeutic index; nonlinear pharmacokinetics (small dose changes produce large level changes); extensive drug interactions via CYP2C9/CYP2C19 and protein binding displacement; osteoporosis; gingival hyperplasia; cognitive impairment; cerebellar atrophy with chronic use; cosmetic effects
- Carbamazepine: Potent CYP3A4 inducer with numerous drug interactions (anticoagulants, statins, calcium channel blockers, PPIs); hyponatremia (especially when combined with diuretics); cardiac conduction effects; aplastic anemia; autoinduction makes dosing unpredictable
- Phenobarbital: Excessive sedation; cognitive impairment; falls risk; enzyme induction; osteoporosis; physical dependence
- Topiramate: Cognitive impairment (word-finding, processing speed) — particularly deleterious in elderly with baseline cognitive vulnerability; metabolic acidosis; weight loss (already a concern in frail elderly); kidney stones
- Valproate: Tremor (mimics or worsens parkinsonism); weight gain; hepatotoxicity risk increases with age; thrombocytopenia; drug interactions; teratogenicity still relevant in reproductive-age elderly
Key Clinical Trials in Elderly Epilepsy
Several landmark studies have shaped ASM selection in the elderly, though the evidence base remains limited compared to younger populations. The VA Cooperative Study (Rowan et al., 2005) was the first large randomized trial comparing lamotrigine, gabapentin, and carbamazepine in 593 elderly patients with new-onset epilepsy. Lamotrigine demonstrated superior retention (the primary outcome, combining efficacy and tolerability) compared to both gabapentin and carbamazepine. The SANAD-II trial (2021) confirmed lamotrigine as the most cost-effective first-line ASM for focal epilepsy, with its tolerability advantage being most pronounced in older adults. The STEP-ONE study further supported levetiracetam as a reasonable alternative, though head-to-head comparisons with lamotrigine remain limited.
Evidence Summary for First-Line ASMs in Elderly
- Lamotrigine: Strongest evidence base — VA Cooperative Study showed best retention at 12 months; SANAD-II confirmed cost-effectiveness; minimal drug interactions; favorable cognitive and mood profile; main limitation is slow titration (8–12 weeks to therapeutic dose)
- Levetiracetam: Most commonly prescribed in practice due to rapid titration, IV availability, no drug interactions, and renal clearance; limited RCT data specifically in elderly; behavioral side effects (irritability, agitation) are the main concern, especially in patients with dementia
- Lacosamide: Growing evidence from observational studies showing good tolerability in elderly; IV formulation for acute settings; PR prolongation requires ECG monitoring; minimal cognitive effects; no head-to-head RCTs vs. lamotrigine in elderly
- Cenobamate: Newer ASM with potent efficacy in drug-resistant epilepsy; limited data in elderly; requires slow titration due to DRESS risk; hepatic metabolism (CYP2C19, CYP3A4) — potential drug interactions to consider
Drug Interactions
Polypharmacy is the norm in elderly patients, making drug interactions a critical consideration in ASM selection. The average older adult takes 5–8 medications. Enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) interact with the most commonly used medications in the elderly, including warfarin, DOACs (apixaban, rivaroxaban via CYP3A4), statins, calcium channel blockers, proton pump inhibitors, and many antidepressants. Non-enzyme-inducing ASMs (levetiracetam, lacosamide, gabapentin, pregabalin) have minimal or no drug interactions and are strongly preferred.
| Common Elderly Medication | Interaction with Enzyme-Inducing ASMs | Clinical Consequence |
|---|---|---|
| Warfarin | Phenytoin, carbamazepine, phenobarbital: increased warfarin metabolism | Subtherapeutic INR; increased stroke/thrombosis risk |
| Apixaban, rivaroxaban | Carbamazepine, phenytoin: CYP3A4/P-gp induction | Reduced DOAC levels; increased thromboembolism risk |
| Atorvastatin, simvastatin | CYP3A4 induction by carbamazepine, phenytoin | Reduced statin levels; inadequate lipid control |
| Amlodipine, diltiazem | CYP3A4 induction | Reduced antihypertensive effect |
| Methadone, oxycodone | CYP3A4/CYP2D6 induction | Reduced opioid levels; pain control failure; potential withdrawal |
| Donepezil, rivastigmine | Minimal direct interaction, but seizure threshold effects | Cholinesterase inhibitors may lower seizure threshold modestly |
| Levothyroxine | Phenytoin, carbamazepine: increased T4 metabolism | Increased levothyroxine requirement; monitor TSH |
Falls, Osteoporosis & Injury
Falls are a major source of morbidity and mortality in elderly patients with epilepsy, resulting from the combined effects of seizures, postictal confusion, ASM-related sedation and ataxia, and osteoporosis-related bone fragility. Enzyme-inducing ASMs accelerate vitamin D metabolism via CYP450 induction, contributing to decreased bone mineral density and a 2–6-fold increase in fracture risk. Valproate also adversely affects bone density through non-CYP mechanisms. People with epilepsy have a 2.4-fold increased risk of hip fractures compared with the general population, and this risk is compounded in the elderly.
| Risk Factor | Mechanism | Management |
|---|---|---|
| Enzyme-inducing ASMs (PHT, CBZ, PB) | CYP450 induction of vitamin D catabolism → decreased calcium absorption → secondary hyperparathyroidism → bone loss | Vitamin D (1,000–2,000 IU/day), calcium (1,000–1,200 mg/day); consider switching to non-enzyme-inducing ASM |
| Valproate | Direct osteoblast inhibition; Fanconi-like tubular dysfunction; increased bone resorption markers | Monitor bone density; vitamin D supplementation; consider alternative ASM |
| ASM-related dizziness/ataxia | Vestibular and cerebellar side effects (carbamazepine, oxcarbazepine, phenytoin); sedation (gabapentin, pregabalin, benzodiazepines) | Dose reduction; switch to lamotrigine, levetiracetam, or lacosamide; physical therapy for balance training |
| Seizure-related falls | Loss of consciousness, postictal confusion, Todd paralysis | Optimize seizure control; seizure precautions; home safety assessment; consider personal alarm device |
| Postural hypotension | Autonomic dysfunction; antihypertensive polypharmacy; ASM-related cardiovascular effects | Orthostatic BP checks; medication review; hydration; compression stockings |
All elderly patients with epilepsy should have baseline bone density assessment (DEXA), vitamin D levels checked (target 25-OH vitamin D ≥30 ng/mL), and supplementation with calcium (1,000–1,200 mg/day) and vitamin D (1,000–2,000 IU/day). ASMs with the least sedation and ataxia (lamotrigine, levetiracetam, lacosamide) are preferred to minimize falls risk. Gabapentin and pregabalin, while lacking drug interactions, are associated with significant dizziness and should be used cautiously. Falls risk assessment using validated tools (Timed Up and Go, Berg Balance Scale) should be performed at baseline and annually.
Cognition & Quality of Life
Cognitive function is a critical concern in elderly epilepsy. Many patients already have cognitive vulnerability from aging, cerebrovascular disease, or early neurodegenerative pathology. The choice of ASM can either protect or further impair cognition, making this consideration paramount in the elderly. ASMs that worsen cognition (topiramate, phenobarbital, phenytoin, benzodiazepines) should be avoided. Lamotrigine has the most favorable cognitive profile in the elderly and may have mild mood-stabilizing benefits. Levetiracetam is cognitively benign but can cause behavioral changes (irritability, agitation, depression) that may be confused with dementia-related behavioral symptoms or exacerbate neuropsychiatric features of neurodegenerative disease.
Quality of life in elderly patients with epilepsy is affected by multiple factors beyond seizure control. Driving restrictions are particularly impactful, as loss of driving independence in an elderly person can lead to social isolation, depression, and loss of autonomy. Depression and anxiety are common comorbidities (affecting 20–30% of elderly patients with epilepsy) and should be actively screened for and treated. Sleep disorders, including obstructive sleep apnea (which is more prevalent in epilepsy), further compound cognitive impairment and seizure frequency. A holistic approach addressing all of these factors — rather than focusing solely on seizure freedom — is essential for optimizing outcomes in elderly epilepsy.
The emerging concept that new-onset epilepsy in the elderly may represent an early biomarker for Alzheimer disease has important implications: subclinical seizures may accelerate cognitive decline, and randomized controlled trials are investigating whether early ASM treatment can slow cognitive deterioration in patients with Alzheimer disease and epileptiform activity. Baseline cognitive assessment with the Montreal Cognitive Assessment (MoCA) is recommended at the time of epilepsy diagnosis, with annual reassessment to track trajectories.
Driving & Safety
Driving regulations for elderly patients with epilepsy follow the same legal framework as for younger adults, but additional considerations include coexisting visual impairment, slower reaction times, and cognitive decline. Most US states require a seizure-free interval of 3–12 months before driving is permitted (varying by state). Physicians should discuss driving restrictions at diagnosis and document the conversation. The balance between maintaining independence (critical for quality of life and mental health in the elderly) and public safety requires individualized assessment considering seizure type, frequency, awareness during seizures, and response to treatment.
Safety Counseling for Elderly Patients with Epilepsy
- Driving: Document seizure-free interval and driving restriction discussion; reassess at each visit; consider occupational therapy driving evaluation if cognitive concerns exist independent of seizures
- Fall prevention: Home safety assessment (remove trip hazards, install grab bars, adequate lighting); consider personal alarm device; physical therapy for balance and gait training
- Bathing: Showers preferred over baths; non-slip mat; shower seat; avoid locking bathroom door; avoid very hot water (scald risk during seizure)
- Kitchen safety: Use rear burners; microwave preferred; avoid deep-fat frying; automatic shut-off timers on stove
- Water safety: No unsupervised swimming; shower only; avoid hot tubs alone
- Height safety: Avoid ladders and unrailed heights; use harness if working at elevation
- Medication adherence: Pill organizers; alarm reminders; caregiver involvement; simplify dosing schedule (once or twice daily preferred)
- SUDEP awareness: Although SUDEP is less common in elderly (more common in young adults with drug-resistant epilepsy), nocturnal seizure monitoring devices may be considered in patients with frequent convulsive seizures
Special Situations: Post-Stroke Epilepsy
Post-stroke epilepsy is the most common identifiable cause of new-onset epilepsy in the elderly and deserves specific attention. Acute symptomatic seizures (occurring within 7 days of stroke) affect 3–6% of ischemic stroke patients and up to 10–16% of hemorrhagic stroke patients. These acute seizures do not necessarily warrant long-term ASM therapy — the decision depends on stroke severity, seizure type, and recurrence risk. In contrast, late post-stroke seizures (occurring >7 days after stroke) constitute unprovoked seizures and meet the diagnostic criteria for epilepsy, warranting long-term ASM treatment.
Risk factors for post-stroke epilepsy include cortical involvement (strongest predictor), hemorrhagic transformation, large infarct volume, severe initial deficit, and younger age at stroke onset (although this remains common in elderly). Post-stroke epilepsy is associated with worse functional outcomes, longer hospitalization, and increased mortality. ASM selection must account for the anticoagulation or antiplatelet therapy that most stroke patients require — avoiding enzyme-inducing ASMs that reduce DOAC and warfarin levels. Levetiracetam is the most commonly used ASM in the acute stroke setting due to IV availability and lack of interactions. For long-term management, lamotrigine or lacosamide are preferred for their favorable interaction and cognitive profiles.
Epilepsy & Dementia: Bidirectional Relationship
There is increasing evidence for a bidirectional association between epilepsy and dementia that has profound implications for the management of epilepsy in the elderly. This relationship operates through multiple mechanisms:
- Alzheimer disease → seizures: AD carries a 6–10-fold increased risk of seizures, particularly in advanced stages; amyloid-beta oligomers increase neuronal excitability; seizures may occur years before clinical dementia diagnosis
- Seizures → neurodegeneration: Histologic studies of epilepsy surgery specimens have revealed amyloid and tau deposition in patients not previously diagnosed with neurodegenerative disease; neuroimaging studies have shown amyloid deposits in patients with drug-resistant epilepsy
- Subclinical epileptiform activity: Detectable only on foramen ovale electrodes or prolonged EEG, subclinical hippocampal seizures and spikes have been documented in patients with Alzheimer disease by Lam et al. (2017) — these may accelerate cognitive decline independent of clinical seizures
- Epidemiologic link: The ARIC study found that late-onset epilepsy of unknown etiology was significantly associated with subsequent dementia development, suggesting that cryptogenic elderly epilepsy may be an early biomarker of neurodegeneration
Active clinical trials are investigating whether levetiracetam can improve cognition in Alzheimer patients with epileptiform activity (LEAS trial at UCSF, ILiAD trial in the UK). A randomized controlled trial by Vossel et al. (2021) found that levetiracetam improved cognitive performance in Alzheimer patients with epileptiform activity compared to placebo, providing preliminary support for the hypothesis that treating subclinical epileptic activity may slow cognitive decline.
Clinical Implications of the Epilepsy-Dementia Link
- All patients with new-onset epilepsy after age 60 should receive cognitive screening (MoCA) at baseline and annually — progressive decline should prompt evaluation for neurodegenerative disease
- New-onset seizures or unexplained cognitive decline in a patient with known Alzheimer disease should prompt EEG to assess for subclinical epileptiform activity
- Choose ASMs with minimal cognitive impact (lamotrigine, levetiracetam, lacosamide) when treating elderly patients with or at risk for dementia
- Avoid ASMs that worsen cognition (topiramate, phenobarbital, phenytoin, benzodiazepines) — these may accelerate the trajectory of neurodegenerative cognitive decline
- Cholinesterase inhibitors (donepezil, rivastigmine) used for AD may modestly lower the seizure threshold — this effect is generally not clinically significant but should be considered in the overall management plan
Practical Approach to New-Onset Epilepsy in the Elderly
- Workup: Brain MRI with epilepsy protocol; routine EEG (consider prolonged/ambulatory if initial EEG is nondiagnostic); basic metabolic panel, CBC, hepatic/renal function, glucose, calcium, magnesium; ECG before starting any sodium channel blocker
- ASM selection: Lamotrigine first-line if titration time permits; levetiracetam if rapid loading needed (available IV); lacosamide as alternative (IV available, check ECG)
- Dosing: Start at 50% of standard adult starting dose; titrate over 4–8 weeks; target the lowest effective dose
- Monitoring: Drug levels at steady state and with any clinical change; renal function annually; bone density at baseline if on enzyme-inducing ASM >5 years; cognitive screening with MoCA at baseline and annually
- Seizure freedom is expected in 60–70% of elderly patients with first-line monotherapy at low to moderate doses — if seizures persist, reevaluate diagnosis before adding a second ASM
Status Epilepticus in the Elderly
Older adults (≥60 years) have the highest incidence of status epilepticus (SE) among adults, with estimates of 68–90 per 100,000/year in those over 60 compared to 18 per 100,000 in younger adults. Mortality from SE in the elderly is 20–40%, substantially higher than in younger adults (10–15%). NCSE accounts for a larger proportion of SE cases in the elderly, and its diagnosis requires a high index of suspicion.
| Feature | SE in Elderly | SE in Younger Adults |
|---|---|---|
| Incidence | 68–90 per 100,000/year | ~18 per 100,000/year |
| Mortality | 20–40% | 10–15% |
| Common etiologies | Stroke, metabolic derangements (hyponatremia, uremia, hyperglycemia), brain tumors, neurodegenerative disease, medication toxicity | ASM nonadherence/withdrawal, alcohol-related, structural lesions, infection |
| Proportion of NCSE | Higher (up to 40–50% of SE presentations); frequently mimics delirium, stroke, or metabolic encephalopathy | Lower proportion of total SE; more commonly convulsive SE |
| Treatment challenges | Benzodiazepine sensitivity (respiratory depression, hypotension); reduced hepatic/renal clearance prolongs drug effects; higher rates of cardiac comorbidity | Generally better tolerated; faster recovery |
| Functional outcome | Significant functional decline in survivors; many require institutionalization; high 30-day readmission rate | Better functional recovery in most cases |
Treatment follows the same stepwise protocol as in younger adults (IV benzodiazepine → second-line ASM loading), but dosing should account for reduced hepatic and renal clearance. Lorazepam remains the first-line benzodiazepine but should be given at reduced doses (2 mg IV rather than 4 mg as initial dose) with careful respiratory monitoring. For second-line treatment, IV levetiracetam is increasingly preferred over phenytoin/fosphenytoin in the elderly due to its favorable hemodynamic and drug interaction profile. Lacosamide IV is an emerging alternative second-line agent with good tolerability in the elderly, though ECG monitoring for PR prolongation is required. Hemodynamic monitoring is essential given the high prevalence of cardiovascular comorbidity, and ICU admission should be considered for all elderly patients with SE.
Discontinuing ASMs in the Elderly
The question of whether to discontinue ASMs in elderly patients who have been seizure-free for many years requires careful consideration. While ASM withdrawal is commonly considered in younger patients after 2–5 years of seizure freedom, the risk-benefit calculation differs in the elderly. The relapse risk after ASM withdrawal in the elderly is estimated at 30–50%, similar to younger populations, but the consequences of relapse are potentially more severe: increased injury risk from falls, cardiovascular stress from convulsive seizures, prolonged postictal confusion, and loss of driving independence that may be difficult to regain.
Conversely, ongoing ASM therapy in the elderly carries cumulative risks of drug interactions, bone loss, cognitive impairment, and polypharmacy-related adverse events. The decision to withdraw ASMs should be individualized, considering the original epilepsy type and etiology, duration of seizure freedom, EEG findings (persistent epileptiform activity predicts higher relapse risk), and the patient's preferences regarding the trade-off between relapse risk and the burden of ongoing medication. If withdrawal is attempted, it should proceed extremely slowly (over 6–12 months), with one drug tapered at a time and close clinical monitoring throughout.
References
- Lezaic N, Roussy J, Masson H, Jette N, Keezer MR. Epilepsy in the elderly: unique challenges in an increasingly prevalent population. Epilepsy Behav. 2020;102:106724.
- Sen A, Jette N, Husain M, Sander JW. Epilepsy in older people. Lancet. 2020;395(10225):735–748.
- Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–1030.
- Johnson EL, Krauss GL, Kucharska-Newton A, et al. Dementia in late-onset epilepsy: the ARIC study. Neurology. 2020;95(24):e3248–e3256.
- Woodward M, Trinka E. Status epilepticus in older adults: a critical review. Epilepsia. 2025;66(3):569–585.
- Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106–115.
- Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of levetiracetam on cognition in patients with Alzheimer disease. JAMA Neurol. 2021;78(11):1345–1354.
- Lam AD, Deck G, Goldman A, et al. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer disease. Nat Med. 2017;23(6):678–680.
- Gourmaud S, Shou H, Irwin DJ, et al. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy. Brain. 2020;143(1):191–209.
- Sillanpaa M, Anttinen A, Rinne JO, et al. Childhood-onset epilepsy five decades later: a prospective population-based cohort study. Epilepsia. 2015;56(11):1774–1783.
- Husein N, Josephson CB, Keezer MR. Understanding cardiovascular disease in older adults with epilepsy. Epilepsia. 2021;62(9):2060–2071.
- Naeije G, et al. EEG patterns compatible with nonconvulsive status epilepticus are common in elderly patients with delirium. Epilepsy Behav. 2014;36:18–21.
- Savage SA, Butler CR, Hodges JR, Zeman AZ. Transient epileptic amnesia over twenty years: long-term follow-up of a case series. Seizure. 2016;43:48–55.
- Keezer MR. Epilepsy comorbidities. Continuum (Minneap Minn). 2025;31(1):232–246.
- Trinka E, Kramer G, Werhahn K. Vascular precursor epilepsy — old wine in new skins? Epilepsy Behav. 2015;48:103–104.
- Stosser S, Bockler S, Ludolph AC, Kassubek J, Neugebauer H. Juxtacortical lesions are associated with seizures in cerebral small vessel disease. J Neurol. 2019;266(5):1230–1235.
- Hickman LB, Stern JM, Silverman DHS, Salamon N, Vossel K. Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology. Front Neurol. 2023;14:1241638.
- French JA, Perucca E, Sander JW, et al. FDA safety warning on the cardiac effects of lamotrigine. Epilepsia Open. 2021;6(1):45–48.
- Bruun E, Virta LJ, Kalviainen R, Keranen T. Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy. Seizure. 2015;31:27–32.
- Cretin B, Philippi N, Sellal F, et al. Can the syndrome of transient epileptic amnesia be the first feature of Alzheimer disease? Seizure. 2014;23(10):918–920.